KRAS Mutation: Comparison of Testing Methods and Tissue Sampling Techniques in Colon Cancer
- 31 January 2010
- journal article
- research article
- Published by Elsevier BV in The Journal of Molecular Diagnostics
- Vol. 12 (1), 43-50
- https://doi.org/10.2353/jmoldx.2010.080131
Abstract
No abstract availableKeywords
Funding Information
- NIH NCI Cancer Center (P30-CA046934)
- NIH NCI Early Detection Research Network (U01-CA85070)
This publication has 29 references indexed in Scilit:
- Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal CancerNew England Journal of Medicine, 2009
- Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal CancerNew England Journal of Medicine, 2009
- High-Resolution Melting Analysis for Rapid Detection ofKRAS, BRAF,andPIK3CAGene Mutations in Colorectal CancerAmerican Journal of Clinical Pathology, 2008
- High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsiesBMC Cancer, 2008
- Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal CancerJournal of Clinical Oncology, 2008
- Molecular Characteristics of Bronchioloalveolar Carcinoma and Adenocarcinoma, Bronchioloalveolar Carcinoma Subtype, Predict Response to ErlotinibJournal of Clinical Oncology, 2008
- Prognostic and Therapeutic Implications of EGFR and KRAS Mutations in Resected Lung AdenocarcinomaJournal of Thoracic Oncology, 2008
- KRAS Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With CetuximabJournal of Clinical Oncology, 2008
- Mutations in the Epidermal Growth Factor Receptor and in KRAS Are Predictive and Prognostic Indicators in Patients With Non–Small-Cell Lung Cancer Treated With Chemotherapy Alone and in Combination With ErlotinibJournal of Clinical Oncology, 2005
- KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or ErlotinibPLoS Medicine, 2005